Last reviewed · How we verify

FORODESINE HYDROCHLORIDE

FDA-approved approved Small molecule ✓ Verified Jun 2026 Quality 5/100

FORODESINE HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 2017).

Forodesine hydrochloride is a medication used to treat various types of leukemia and lymphoma, including T-cell leukemia, chronic lymphocytic leukemia, and lymphoma. It is administered as an infusion to patients with advanced disease.

At a glance

Generic nameFORODESINE HYDROCHLORIDE
ModalitySmall molecule
PhaseFDA-approved
First approval2017

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about FORODESINE HYDROCHLORIDE

What is FORODESINE HYDROCHLORIDE?

FORODESINE HYDROCHLORIDE is a Small molecule drug.

When was FORODESINE HYDROCHLORIDE approved?

FORODESINE HYDROCHLORIDE was first approved on 2017.

What development phase is FORODESINE HYDROCHLORIDE in?

FORODESINE HYDROCHLORIDE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing